Schizophrenia is a leading worldwide mental health problem. It is also one of the common and challenging problems in Nepal. Risperidone and olanzapine is one of the major antipsychotic drug used for schizophrenia patients, however their efficacy is not compared in Nepal. To assess the efficacy of risperidone and olanzapine in schizophrenia patients in Nepalese context. An open-label, randomized, comparative, prospective study was done for 6 weeks. Total of 63 patients attending Psychiatry OPD in Jan to July 2008 at TUTH who could be available for close follow up were enrolled with consent.
Introduction
Schizophrenia is a major psychotic disorder. The lifetime morbidity risk for schizophrenia is estimated to be 1.0%
1 and appears to be the same for men and women up to age 60 years. profile. 5 In Nepal also, there is extensive use of these two drugs and to see the results in the Nepalese population the study was conducted.
Materials and methods
The 4(6.3%) were doing business, 7(11.1%) were farmers, 1(1.6%) was a teacher, 7(11.1%) were housewives, 15(23.8%) were student, 24(38.1%) were unemployed and 5(7.9%) were doing service. There was no statistically significant difference in the occupational groups of the two study groups (Chi-square p=0.508).
47(74.6%) belonged to joint family and 16(25.4%) belonged to nuclear family.
A 2(3.2%) belonged to low SES, 60(95.2%) belonged to middle SES and 1(1.6%) belonged to the high SES group. There was no statistically significant difference in the socioeconomic status of the patients enrolled to the study groups (Chi-square p=0.217).
31(49.2%) were from the rural community and 32(50.8%) were from the urban community. There was no statistically significant difference in the locality of the patients in the study groups (Chi-square p=0.617).
Baseline scores of patient in both the groups were comparable. With the introduction of drugs the change from baseline after 1, 2, 4 and 6 were recorded and the significance was checked with paired t test which is shown in the graphs with similar pattern of clinical improvement in both groups. Studies using multiple doses of risperidone 12 have
shown that risperidone causes a dose-related increase in extrapyramidal side effects, with risk highest in doses greater than 6 mg/day. 13 Although precise estimates of the incidence of akathisia are not available, it appears to be less common with low-potency first-generation antipsychotics and even more infrequent with secondgeneration antipsychotic agents. In this regard, however, it is important to note that risperidone may cause akathisia at the higher end of the dose range. 14 The patient developed akathisia in a dose-dependent manner at dosages between 10 and 15 mg daily of olanzapine, but no EPS.
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Conclusion
The results of the study demonstrate the efficacy in the Nepalese context in a six week open-label randomized study. Risperidone (4-6mg) and olanzapine (15-20mg) were similarly effective in all the positive, negative and general psychopathology of schizophrenia in the acute phase. The onset of action was also similar for both the drugs. Risperidone was found to have extrapyramidal symptoms and sexual side-effects while with olanzapine excessive sedation and weight gain was seen in the six week study period. The use of anti-eps drugs was more so in patients treated with risperidone. Cost of acquisition of olanzapine is higher than risperidone but need of anti-eps drugs, need for sedatives raises the cost of treatment with risperidone lessening the cost gap between the two drugs. Long term tolerability and efficacy, continuation of the improvement in the maintenance phase, improvement in the quality of life and the metabolic disturbances being found on long term needs to be considered. Thus both the drugs are similar by efficacy in the short and long term and the cost factor also needs to be considered.
